Tablettákat diabetes 2 - type kezelés

Az enziminduktorok, mint pl. Fontbonne, A, Eschwege, E: The epidemiological link between insulin levels and atherosclerotic complications.

Orv Hetil —, Diabetologia 42 Suppl. Diabet Med —, J Am Coll Cardiol —, Diabetologia —, Horm Metab Res —, Malaisse, WJ: Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family.

Diabetes —, Malaisse, WJ: Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies.

Eur J Clin Invest —29, Endocrine 8: —, Eur J Pharmacol —, Owens, DR: Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes. Eur J Clin Invest 29 Suppl.

De Gruyter, Berlin-New York, Medicina, Budapest, Owens, DR: Repaglinide — prandial glucose regulator: a new class of oral antidiabetic drugs. Diabet Med 15 Suppl. Brit J Clin Pharmacol P, Diabetes Care —, Eur J Clin Pharmacol —, Diabetologia 41 Suppl.

Diab Res Clin Pract —39, Dambso, P, Clauson, P, Marbury, TC, Windfeld, K: A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.

Diabetologia 43 Suppl.

A randomized, semi-blinded, paralell-group, multicentre trial. Diabetes A,